Stock listing

NASDAQ:RGLS Regulus Therapeutics Inc Stock

Follow Regulus Therapeutics Inc into a list and get an email when it puts out news.

Last close · NASDAQ:RGLS

$8.16 USD

Close on Jun 24, 2025 · No longer trades

Jun 29, 2022 to last close +288.6% · weekly closes, Jun 29, 2022 – Jun 24, 2025
Lowest – highest close
$0.793 – $8.30 USDSince Jun 29, 2022 · lowest Mar 27, 2023 · highest Jun 9, 2025

Delisted NASDAQ:RGLS no longer trades. Its last trading date is unknown. Company history and updates stay available on this page.

Ticker
NASDAQ:RGLS
Asset type
Stock
Exchange
NASDAQ
Currency
USD

Regulus Therapeutics Inc on 6ix

Calls
7 calls with a replay · 7 with a transcript · latest Nov 10, 2022
Decks
4 decks · latest Mar 27, 2025

Events

CallWhenStatus
Regulus Therapeutics (RGLS) Q3 2022 Earnings CallThu, Nov 10, 2022 · 5:00 PM ETReplay
Regulus Therapeutics (RGLS) Q2 2022 Earnings CallThu, Aug 11, 2022 · 5:00 PM ETReplay
Regulus Therapeutics (RGLS) Q1 2022 Earnings CallThu, May 12, 2022 · 5:00 PM ETReplay
Regulus Therapeutics (RGLS) Q4 2021 Earnings CallThu, Mar 10, 2022 · 5:00 PM ETReplay
Regulus Therapeutics (RGLS) Q3 2021 Earnings CallWed, Nov 10, 2021 · 5:00 PM ETReplay
Regulus Therapeutics (RGLS) Q2 2021 Earnings CallTue, Aug 10, 2021 · 5:00 PM ETReplay
Regulus Therapeutics (RGLS) Q1 2021 Earnings CallThu, May 13, 2021 · 5:00 PM ETReplay

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (March 2025)Technical10 slidesMar 27, 2025
Investor Presentation (October 2021)Investor deck36 slidesOct 18, 2021
Rare & Orphan Disease Summit (May 2021)Conference30 slidesMay 21, 2021
Investor Presentation (December 2020)Investor deck43 slidesDec 1, 2020

Open Decks

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Garry E. Menzel
Other companies: Adaptimmune Therapeutics PLC (Non-Executive Director · Since at least Jun 1, 2023); Stoke Therapeutics, Inc. (Director · Since at least Aug 13, 2020); Black Diamond Therapeutics, Inc. (Operating Partner, GHO Capital Partners LLP · Since at least Jan 29, 2020); Tcr2 Therapeutics Inc (President and CEO, Director · Feb 13, 2019 – Jun 1, 2023 · Past); DaVita Inc. (Senior Vice President, Finance · Sep 9, 2013 – Sep 9, 2013 · Past)
COO & Executive VP, Finance · Oct 4, 2012 – Dec 11, 2012 · Past
Stelios Papadopoulos
Other companies: Ovid Therapeutics Inc. (Director, Member of the Audit and Compensation Committees · Since at least Mar 1, 2025); Exelixis, Inc. (Chair of the Board, Exelixis, Inc. · Since at least May 24, 2012); BG Medicine Inc (Director · Since at least Nov 9, 2011); Eucrates Biomedical Acquisition Corp. (Director · Oct 23, 2020 – Nov 24, 2020 · Past); Biogen Inc. (Director · Jun 8, 2012 – Jun 15, 2022 · Past)
Director · Since at least Oct 4, 2012
Mark Foletta
Other companies: Enanta Pharmaceuticals, Inc. (Director · Since at least Jun 29, 2020); AMN Healthcare Services Inc (Director · Since at least Nov 27, 2017); DexCom, Inc. (Director · Since at least Nov 27, 2017); Tocagen Inc (EVP & Chief Financial Officer · Dec 8, 2017 – Oct 4, 2019 · Past)
Director · Dec 4, 2017 – Dec 4, 2017 · Past
Jason Raleigh Nunn
Other companies: Addex Therapeutics Ltd (Director · Since at least Mar 18, 2026); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Trevena, Inc. (Director · May 16, 2019 – Jun 13, 2024 · Past)
Director · Since at least Jun 6, 2019
Neil Gibson
Other companies: Instil Bio, Inc. (Board Member · Since at least Mar 18, 2021); Shattuck Labs, Inc. (Director · Since at least Oct 8, 2020); Tcr2 Therapeutics Inc (Director · Feb 13, 2019 – Jun 1, 2023 · Past)
Chief Scientific Officer · Oct 4, 2012 – Jan 28, 2015 · Past
Pascale Witz
Other companies: Revvity, Inc. (Director · Since at least Oct 27, 2017); Tesaro Inc (Director · May 10, 2018 – Jan 22, 2019 · Past); Horizon Pharma PLC (Director · Aug 2, 2017 – Aug 2, 2018 · Past)
Director · Since at least Jun 1, 2017
Daniel R Chevallard
Other companies: LENZ Therapeutics, Inc. (Chief Financial Officer · Since at least Mar 21, 2024); Viracta Therapeutics Inc (CFO and COO · Mar 26, 2021 – Mar 12, 2024 · Past)
Chief Financial Officer · May 4, 2017 – Jul 1, 2019 · Past
David Baltimore
Other companies: Amgen Inc. (Director · Mar 30, 2016 – Apr 27, 2018 · Past); Immune Design Corp (Director · Jan 4, 2016 – Apr 2, 2019 · Past)
Director · Since at least Jun 2, 2016
Simos Simeonidis
Other companies: Sarissa Capital Acquisition Corp (Senior Managing Director · Oct 20, 2020 – Oct 20, 2020 · Past)
Director · Jun 6, 2019 – Jun 9, 2022 · Past
Timothy Michael Wright
Other companies: Schrodinger, Inc. (Director · Feb 5, 2020 – Feb 10, 2020 · Past)
Chief R & D Officer · Dec 4, 2017 – Feb 5, 2019 · Past
All 14 people
PersonSeat
Alice Shih-hou HuangDirector · Since at least Jan 6, 2021
Christopher Ray AkerSr. VP & General Counsel · Since at least Jan 1, 2019
Denis DryginChief Scientific Officer · Aug 3, 2020 – Mar 1, 2022 · Past
Hugh RosenDirector · Since at least Jun 2, 2016

Open People

Log in to ask 6ix AI your own questions about Regulus Therapeutics Inc.